Background {#Sec1}
==========

Osteoporosis (OP) is a common contributor to hip and spine fractures in worldwide patients \[[@CR1], [@CR2]\]. OP is a global public health problem and affects appropriately 75 million people in the USA \[[@CR3]\]. The ideal therapeutic goal is to increase the bone mass, and subsequently decrease the risk of fracture \[[@CR4]\]. Bisphosphonates, a classic antiresorptive agent, is currently the most common therapy for osteoporosis \[[@CR5]\]. However, compliance was the major concern of bisphosphonates \[[@CR6]\]. Prolonged medication and possible complications limited the effects of bisphosphonates for OP patients.

Receptor activator of nuclear factor-kB ligand (RANKL) is a cytokine that is essential for osteoclast survival and differentiation. Thus, through blocking the RANKL could inhibit the differentiation of osteoclast and increase the bone mass. Denosumab, a fully human monoclonal antibody against the RANKL, could potently reduce bone resorption with accompanying increases in bone mineral density (BMD). Denosumab 60 mg was always subcutaneously given per 6 months and thus the compliances may be well. Previously, a meta-analysis that compared denosumab with bisphosphonates for OP patients has been published \[[@CR7]\]. However, several disadvantages existed in the meta-analysis. (1) Only four randomized controlled trials (RCTs) were included and the sample was relatively small. (2) They only compared with alendronate, but neglect other bisphosphonates. With new evidence emerging, we performed a meta-analysis that compares denosumab with bisphosphonates for bone loss in postmenopausal osteoporosis patients. We hypothesized that denosumab was superior than bisphosphonates in reducing bone loss in postmenopausal osteoporosis patients and thus reduce the risk of fracture.

Methods {#Sec2}
=======

The present meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISRMA) \[[@CR8]\].

Search strategy {#Sec3}
---------------

Published literatures, only including RCTs, were searched in the following electronic databases: PubMed, Embase, Web of Science, Cochrane Library, and Google database from inception to April 20 2018. The keywords and corresponding Mesh terms of osteoporosis and denosumab were referred to published meta-analysis \[[@CR9]\]. The keywords and corresponding Mesh term of bisphosphonates was referred to Lou's protocol \[[@CR10]\]. Detailed search keywords and Mesh terms can be seen in Additional file [1](#MOESM1){ref-type="media"}. Besides, references of all included articles were also reviewed. There was no language limited and no publication restriction.

Inclusion criteria and exclusion criteria {#Sec4}
-----------------------------------------

### Inclusion criteria {#Sec5}

Candidate articles would be included if they met the following criteria: (i) population: patients were diagnosed with osteoporosis and did not take other oral anti-osteoporosis drugs; (ii) intervention: subcutaneously administered denosumab 60 mg per 6 months; (iii) comparison: administration with bisphosphonates, regardless of the dose and intervals; (iv) with one or more of the outcomes described below: risk of fracture, total adverse events (AEs), withdrawn due to AEs, change in one-third radius BMD, change in total hip BMD, change in lumbar spine BMD, and change in femoral neck BMD; and (v) study design: RCTs.

### Exclusion criteria {#Sec6}

Candidate articles would be excluded if they met the following criteria: (i) patients were diagnosed with other type of osteoporosis (androgen-deprivation therapy or breast cancer); (ii) intervention: combined denosumab with other drugs; and (iii) non-RCTs.

Assessment of study quality {#Sec7}
---------------------------

Two reviewers (Jiaqi Wu and Qingsheng Zhang) independently assessed the quality of RCTs in accordance with Cochrane Collaboration's tool for assessing the risk of bias. If there was conflict between the two reviewers, a third reviewer is consulted and they discussed to solve the controversy. The tool included the following items: random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting. We further performed Kappa test to increase the stability of our meta-analysis.

Data extraction {#Sec8}
---------------

Two reviewers independently extracted the following data and written in a pre-generated Excel file: first author's name, publication year, mean age, intervention, comparison, outcomes, and duration. First outcome was the risk of fracture, since fracture has a heavy economic burden to the society and patients. Second outcomes were change in one-third radius BMD, change in total hip BMD, change in lumbar spine BMD, and change in femoral neck BMD. Safety outcomes included total AEs, withdrawn due to AEs.

Statistical analysis {#Sec9}
--------------------

In consideration of the clinical heterogeneity, we used random-effect model for all of the outcomes. Outcomes were divided into two categories (dichotomous data and continuous data). Dichotomous data were expressed as proportions, such as risk of fracture, AEs, and withdrawn due to AEs; the intervention effect was expressed as a risk ratio (RR) and corresponding confidence intervals (CI). Continuous data were meta-analyzed in terms of the weighted mean difference (WMD) and associated 95% CI. Publication bias was assessed by funnel plot, Begg's test, and Egger's test. Subgroup analysis was performed according to the comparator treatment, population who had been prescribed a treatment for osteoporosis and high or unclear risk of bias.

Pooled data were assessed for heterogeneity using the *I*^2^ tests. Heterogeneity was defined as absent when *I*^2^ was between 0 and 25%; low, between 25.1 and 50%; moderate, between 50.1 and 75%; or high, between 75.1 and 100%.

Result {#Sec10}
======

Search results {#Sec11}
--------------

Systematic search of PubMed, Embase, Web of Science, Cochrane Library, and Google database turned up 376 potentially eligible studies, and no additional records were found during manual searches of reference lists. After removing 118 duplicate studies using Endnote X7, another 245 studies were excluded based on their titles and abstracts. The remaining 13 studies were read in full, and 2 were excluded because they failed to satisfy the selection criteria. In the end, 11 RCTs involving 5446 patients (denosumab = 2873, bisphosphonates = 2573) \[[@CR11]--[@CR21]\] were included in the systematic review and meta-analysis. Details of study identification, screening, and selection are given in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow of trials through the meta-analysis

Characteristics of included studies {#Sec12}
-----------------------------------

The publication years were raged from the year of 2006 to 2016. Altogether involving 5449 cases of osteoporosis. Six studies were performed in the USA, 1 in Spain, 1 in UK, 2 in Canada, and 1 France and 1 Australia. The dose of denosumab was administration with subcutaneous injection 60 mg every 6 months. We included four types of bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid). The duration of follow-up was ranged from 12 to 24 months. Detailed information of the characteristic can be obtained in Table [1](#Tab1){ref-type="table"}.Table 1The general characteristic of the included RCTsAuthorSample (*n*)Mean age (year)InterventionComparisonDuration (month)OutcomesStudyCountryInterventionComparisonInterventionComparisonBeck 2008 \[[@CR11]\]USA39386363Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly2456RCTsLewiecki 2007 \[[@CR12]\]USA3194762.362.8Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly241RCTsMcClung 2006 \[[@CR13]\]USA474763.162.8Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly12123,467RCTsBrown 2009 \[[@CR14]\]Spain59459564.164.6Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly121,234,567RCTsKendler 2010 \[[@CR15]\]USA25325166.968.2Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly12234,567RCTsFreemantle 2012 \[[@CR16]\]UK12612465.165.3Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly242345RCTsKendler 2011 \[[@CR17]\]Canada25325166.968.2Sc denosumab injections (60 mg Q6M)Oral alendronate 70 mg once weekly1256RCTsRecknor 2013 \[[@CR18]\]USA41741667.266.2Sc denosumab injections (60 mg Q6M)Oral ibandronate 150 mg once month1212,346RCTsRoux 2014 \[[@CR19]\]France42240267.867.7Sc denosumab injections (60 mg Q6M)Oral risedronate 150 mg once month12123,456RCTsMiller 2016 \[[@CR20]\]USA32032065.966.1Sc denosumab injections (60 mg Q6M)intravenous zoledronic acid 5 mg once year12123,457RCTsSeeman 2010 \[[@CR21]\]Australia838260.360.7Sc denosumab injections (60 mg Q6M)oral alendronate 70 mg once weekly1223RCTs1, risk of fracture; 2, AEs, 3 withdrawn due to AEs; 4, change in total hip BMD; 5, change in femoral neck BMD; 6, change in lumbar spine BMD; 7, change in one-third radius BMD

Quality of the included RCTs {#Sec13}
----------------------------

Details of the risk of bias are summarized in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. Overall, ten trials were categorized as at low risk of bias, one as being unclear, and none being at high risk of bias. Only one study did not introduce the random sequence generation and thus categorized as unclear risk of bias. Since we did not know whether the funding institution participated into the experimentation and thus all of the other bias was categorized as unclear risk of bias.Fig. 2The risk of bias summary, +, no bias; −, bias;?, bias unknownFig. 3Risk of bias of graph of the included randomized controlled trials

Results of meta-analysis {#Sec14}
------------------------

### Risk of fracture {#Sec15}

Six trials totaling 4218 patients provided data on risk of fracture. Compared with bisphosphonates treatment, administration with denosumab has no benefit for reducing the risk of fracture (RR 1.13; 95% CI 0.82--1.55; *P* = 0.466) (Fig. [4](#Fig4){ref-type="fig"}), with no heterogeneity (*I*^2^ = 0.0%). For the meta-analysis of denosumab versus bisphosphonates on risk of fracture, there was no evidence of publication bias by inspection of the funnel plot (Fig. [5](#Fig5){ref-type="fig"}) and formal statistical tests (Egger test, *P* = 0.85; Begg test, *P* = 0.69) **(**Figs. [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). To further increase the persuasion of this outcome, we performed a sensitivity analysis using leave out one study in turn and results shown that after leaving out one study in turn, the overall effect size was not changeable (Fig. [8](#Fig8){ref-type="fig"}).Fig. 4Forest plots of the included studies comparing the risk of fractureFig. 5Funnel plot of the risk of fractureFig. 6Egger test for risk of fractureFig. 7Begg's test for risk of fractureFig. 8Sensitivity analysis for risk of fracture

Table [2](#Tab2){ref-type="table"} presents the results of subgroup analyses. The findings of decreased risk of fracture were consistent in all subgroup analyses.Table 2Subgroup analysis of the risk of fractureSubgroupNo. of included studiesRR (95% CI)*I*^2^ (%)Comparator treatmentAlendronate31.10 (0.95, 1.23)12.3Ibandronate11.08 (0.89, 1.16)--Risedronate11.23 (0.75, 1.08)--Zoledronic acid10.86 (0.74, 0.99)--Population who had been prescribed a treatment for osteoporosisNo (\< 100% of participants)41.15 (0.67, 1.22)0.0No (\> 100% of participants)31.12 (0.85, 1.08)0.0High or unclear risk of biasNo21.09 (0.74, 1.26)0.0Yes51.31 (0.89, 1.14)0.0

AEs {#Sec16}
---

Seven trials totaling 4776 patients provided data on AEs. There was no significant difference between denosumab and bisphosphonates in terms of the AEs (RR 1.00; 95% CI 0.96--1.04; *P* = 0.957) (Fig. [9](#Fig9){ref-type="fig"}), with little heterogeneity (*I*^2^ = 14.6%).Fig. 9Forest plots of the included studies comparing the AEs

Withdrawn due to AEs {#Sec17}
--------------------

Eight trials totaling 4816 patients provided data on withdrawn due to AEs. There was no significant difference between denosumab and bisphosphonates in terms of the withdrawn due to AEs (RR 0.68; 95% CI 0.34--137; *P* = 0.280) (Fig. [10](#Fig10){ref-type="fig"}), with middle heterogeneity (*I*^2^ = 50.8%).Fig. 10Forest plots of the included studies comparing the withdrawn due to AEs

Change in total hip BMD {#Sec18}
-----------------------

Compared with bisphosphonates, denosumab for osteoporosis patients further increased change in total hip BMD (MD 1.05%; 95% CI 0.85 to 1.26; *P* = 0.000, Fig. [11](#Fig11){ref-type="fig"}) with middle heterogeneity (*I*^2^ = 31.4%).Fig. 11Forest plots of the included studies comparing the change in total hip BMD

Change in femoral neck BMD {#Sec19}
--------------------------

Compared with bisphosphonates, denosumab for osteoporosis patients further increased change in femoral neck BMD, (WMD = 1.06%; 95% CI 0.79 to 1.32; *P* = 0.000, Fig. [12](#Fig12){ref-type="fig"}) with middle heterogeneity (*I*^2^ = 30.5%).Fig. 12Forest plots of the included studies comparing the change in femoral neck BMD

Change in lumbar spine BMD {#Sec20}
--------------------------

Compared with bisphosphonates, denosumab for osteoporosis patients further increased change in lumbar spine BMD (WMD = 1.55%; 95% CI 1.09 to 2.02; *P* = 0.000, Fig. [13](#Fig13){ref-type="fig"}) with high heterogeneity (*I*^2^ = 72.2%).Fig. 13Forest plots of the included studies comparing the change in lumbar spine BMD

Change in one-third radius BMD {#Sec21}
------------------------------

Compared with bisphosphonates, denosumab for osteoporosis patients further increased change in one-third radius BMD (WMD = 0.83%; 95% CI 0.34 to 1.31; *P* = 0.000, Fig. [14](#Fig14){ref-type="fig"}) with high heterogeneity (*I*^2^ = 61.1%).Fig. 14Forest plots of the included studies comparing the change in one-third radius BMD

Discussion {#Sec22}
==========

Our meta-analysis comprehensively and systematically reviewed the current available literature and found that (1) denosumab compared with bisphosphonates significantly increased change in total hip, femoral neck, lumbar spine, and one-third radius BMD for postmenopausal osteoporosis patients. The evidence of benefit was consistent when we further performed a sensitivity analysis; (2) denosumab has no benefit for reducing the risk of fracture when compared with bisphosphonates; (3) and the occurrence of AEs and withdrawn due to AEs were similar in denosumab and bisphosphonates.

Several meta-analyses on the topic have been published \[[@CR7], [@CR9]\]. However, differences between current meta-analysis and the previous ones should be noted. First, these previous meta-analyses identified other anti-osteoporosis drugs (teriparatide) and placebo as comparison. Therefore, a large heterogeneity existed in previous meta-analyses. Second, several literatures were left out in previous meta-analyses and thus potential publication bias existed in their study. Beaudoin et al. \[[@CR9]\] compared denosumab with other treatments to prevent or treat osteoporosis. We noted that they included patients that prescribed daily or weekly bisphosphonate therapy ≥ 1 month. Thus, we could not determine the real effects of denosumab for postmenopausal osteoporosis. Lin et al. \[[@CR7]\] conducted a meta-analysis that compared denosumab and alendronate in postmenopausal women with osteoporosis. However, only four heterogeneous RCTs were included. Current meta-analysis added statistical power of at least 7 RCTs and appropriately 1900 cases. In summary, our current meta-analysis was the latest and the most comprehensive one.

The difference between denosumab and bisphosphonates for clinical outcomes were change in the skeletal BMD. Denosumab has a greater antiresorptive effect than bisphosphonates. The effects of bisphosphonates for preventing bone loss mainly need bisphosphonates binding to bone mineral. Denosumab mainly through direct combined with the RANKL and inhibit the survival and differentiation of osteoclast. In general, increasing of the BMD means a decrease in the occurrence of fracture. However, we did not observe any significant difference between the risk of fracture. The reason may be as follows: (1) gain in BMD over a relatively short time was not enough to reduce the risk of fracture, and (2) the occurrence of fracture was affected by many factors. Murad et al. \[[@CR22]\] conducted a network meta-analysis and compared with different drugs for preventing fragility fractures. Results show that teriparatide, bisphosphonates, and denosumab are the most effective in reducing the risk of fragility fractures.

When a new drug was popularized and applied in clinical trials, AEs were the major concern. In current meta-analysis, we compared total AEs and withdrawn due to AEs. Results show that there was no significant difference between the total AEs and withdrawn due to AEs. Since immune cells also have the RANKL receptor and the major concern was the denosumab for immune function. Later, Stolina et al. \[[@CR23]\] and Bekker et al. \[[@CR24]\] suggest that denosumab has no effects on RANKL/RANK pathway in immune system.

Our meta-analysis also had limitations. (1) Included studies were sponsored by drug dealer and thus may resulted in performance bias. (2) We included osteoporosis patients that came from different countries and with different diagnostic criteria. Thus, the clinical heterogeneity was imminent. (3) Duration of follow-up was relatively short in the included studies and thus some severe complications were underestimated.

Conclusion {#Sec23}
==========

Our meta-analysis suggested that denosumab but not bisphosphonates significantly increased change in total hip, femoral neck, lumbar spine, and one-third radius BMD for postmenopausal osteoporosis patients. Current evidence suggested no benefit of denosumab for reducing risk of fracture than bisphosphonates. More long-term follow-up RCTs are needed to identify the potential complications of denosumab.

Additional file
===============

 {#Sec24}

Additional file 1:Detailed search keywords and Mesh terms in PubMed database. (DOCX 14 kb)

AEs

:   Adverse events

BMD

:   Bone mineral density

CI

:   Confidence intervals

OP

:   Osteoporosis

RANKL

:   Receptor activator of nuclear factor-kB ligand

RCTs

:   Randomized controlled trials

RR

:   Risk ratio

WMD

:   Weighted mean difference
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